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Abstract
Regulation of innate inflammatory responses against the enteric microbiota is essential for the
maintenance of intestinal homeostasis. Key participants in innate defenses are macrophages. In
these studies, the basic leucine zipper protein, NFIL3, is identified as a regulatory transcription
factor in macrophages, controlling IL-12 p40 production induced by bacterial products and the
enteric microbiota. Exposure to commensal bacteria and bacterial products induced NFIL3 in
cultured macrophages and in vivo. The Il12b promoter has a putative DNA-binding element for
NFIL3. Basal and LPS-activated NFIL3 binding to this site was confirmed by chromatin
immunoprecipitation. LPS-induced Il12b promoter activity was inhibited by NFIL3 expression
and augmented by NFIL3-short hairpin RNA in an Il12b-bacterial artificial chromosome-GFP
reporter macrophage line. Il12b inhibition by NFIL3 does not require IL-10 expression, but a C-
terminal minimal repression domain is necessary. Furthermore, colonic CD11b+ lamina propria
mononuclear cells from Nfil3−/− mice spontaneously expressed Il12b mRNA. Importantly, lower
expression of NFIL3 was observed in CD14+ lamina propria mononuclear cells from Crohn’s
disease and ulcerative colitis patients compared with control subjects. Likewise, no induction of
Nfil3 was observed in colons of colitis-prone Il10−/− mice transitioned from germ-free to a
conventional microbiota. In conclusion, these experiments characterize NFIL3 as an Il12b
transcriptional inhibitor. Interactions of macrophages with the enteric microbiota induce NFIL3 to
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limit their inflammatory capacity. Furthermore, altered intestinal NFIL3 expression may have
implications for the pathogenesis of experimental and human inflammatory bowel diseases.
The gastrointestinal tract represents a complex interface between the enteric microbiota and
immune cell populations. A multitude of microorganisms reside in the intestinal lumen
separated from the body’s largest reservoir of macrophages by a single epithelial cell layer.
Macrophages typically produce inflammatory cytokines in response to microbial Ags
through pathogen recognition receptors such as TLRs. However, to prevent excessive
inflammatory responses to commensal microbes, intestinal macrophages have acquired a
unique phenotype, and unlike their systemic counterparts, they do not produce inflammatory
cytokines in response to enteric bacteria (1). Consequently, loss of macrophage tolerance to
the enteric microbiota is an important and proximal event in the pathogenesis of the
inflammatory bowel diseases (IBDs) (2).
IL-12 family members play a central role in experimental models of intestinal inflammation
(3, 4) and human IBD (5, 6). IL-12 and IL-23 are heterodimeric cytokines composed of a
common p40 subunit in addition to a p35 and p19 subunit, respectively (7). The common
subunit IL-12 p40 (Il12b) is expressed in macrophages and is highly induced by microbial
stimuli such as LPS (8). Therefore, factors that regulate Il12b expression in macrophages are
likely to be central determinants of intestinal homeostasis and inflammation.
NFIL3 (also called as E4BP4), a mammalian basic leucine zipper transcription factor, was
first identified through its ability to bind and repress viral promoter sequences (9). NFIL3 is
constitutively expressed in a variety of tissues, including spleen, prostate, testis, ovary,
heart, brain, lung, liver, skeletal muscle, and intestine (9). Recently, NFIL3-deficient
(Nfil3−/−) mice have been independently developed by three groups. Two groups reported
defects in NK cell development, with absence of NK cells in Nfil3−/− mice (10, 11).
Kashiwada et al. (12) then described that NFIL3 was essential for IgE class switching in B
cells. Although these initial reports did not note phenotypic abnormalities in macrophages,
they by no means exclude important functional defects. Indeed, NFIL3 was previously
identified as an LPS-inducible transcription factor in murine bone marrow-derived
macrophages (BMDMs), although functional correlates were not described (13).
In this article, we identify NFIL3 as an inhibitor of Il12b transcription in macrophages. Our
results suggest that NFIL3 is a physiologic regulator of IL-12/-23 during host-enteric
commensal interactions and contributes to intestinal homeostasis.
Materials and Methods
Mice
Wild-type (WT) and Myd88−/− mice (C57BL/6 background) in specific pathogen-free (SPF)
conditions were used for BMDM derivation. Nfil3−/− mice were generated by gene-targeting
strategies, as reported previously (12), and bred with C57BL/6 mice for at least 10
generations. WT and Il10−/− mice (129/SvEv background) were used for all germ-free (GF)
transition experiments. GF mice were maintained in the Gnotobiotic Core at the University
of North Carolina. Mice housed in GF conditions were transitioned to an SPF environment
at 6 wk of age, as previously described (14). All animal experiments were in accordance
with protocols approved by the Institutional Animal Care and Use Committee of the
University of North Carolina School of Medicine and the University of Iowa Carver College
of Medicine.
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LPS from Salmonella enteritidis (Sigma, St. Louis, MO) was repurified by modified phenol
extraction as previously described (15). M-CSF was obtained from PeproTech (Rocky Hill,
NJ). Blocking rat IgG2a anti–IL-10 mAb and an isotype control were purchased from
eBioscience (San Diego, CA).
Il12b-GFP bacterial artificial chromosome transformed macrophages
Transgenic mice were generated containing a 200-kb Il12b bacterial artificial chromosome
(BAC) transgene (generated by S.T.S.). Before micro-injection, BAC recombineering in
Escherichia coli introduced a GFP cDNA into the Il12b transcription unit. Next, a
transformed macrophage line from the Il12b-GFP BAC transgenic mice was created by
infection of BMDMs with the murine oncogenic J2 retrovirus (16). Clonal lines were
screened by flow cytometry to identify lines that support efficient induction of GFP
fluorescence in response to LPS stimulation.
Cell isolation
BMDMs were cultured as described previously (17). Mouse colonic lamina propria
mononuclear cells (LPMCs) were isolated by an enzymatic method and separated into
CD11b+ cells using anti-CD11b microbeads (Miltenyi Biotec, Auburn, CA) (1). Human
CD14+ LPMCs were isolated from surgically resected colons or ilea from patients with IBD
(Crohn’s disease, n = 8; ulcerative colitis, n = 8) or control patients (n = 8) as described
previously (5). Diagnoses of IBD were based on the clinical, radiographic, endoscopic, and
histological findings according to established criteria. The degree of inflammation was
histologically moderate to severe in all Crohn’s disease and ulcerative colitis patients.
Control colonic resections were obtained from unaffected areas from patients with colon
cancer. Experiments were approved by the Institutional Review Board of Keio University
School of Medicine and Yokohama Municipal Hospital, Japan. Written informed consent
was obtained from all patients.
Quantitative RT-PCR
Quantitative real-time RT-PCR was performed as described previously (18). To evaluate the
expression of NFIL3-regulated genes, we used an RT2 Profiler PCR array kit
(PAMM-073E; SA Biosciences), which profiles inflammatory response cytokines and
chemokines. NFIL3 expression in human CD14+ cells was determined using TaqMan FAM-
labeled probe for NFIL3 obtained from Assays on Demand (Applied Biosystems).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation (ChIP) was performed with ChIP-IT Express kit (Active
Motif, Carlsbad, CA) (19). Sample DNAs were also analyzed on 2% agarose gels. Ab for
NFIL3 was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Primers for NFIL3
binding to the Il12b promoter were: forward 5′-TTGCCGCCTCTATTCACCTTAG-3′,
reverse 5′-GGAAATGACTTCGGGGTGTG-3′.
Lentivirus-mediated gene transduction
Lentiviral transduction was optimized for the FuGENE Transfection Reagent (Roche,
Indianapolis, IN) in HEK293T cells. Virus was collected at 40 and 60 h after transduction
and concentrated with PEG-it virus precipitation solution (System Biosciences, Mountain
View, CA). Two hundred micro-liters virus was added to 6 × 105 BMDMs from WT or
Nfil3−/− mice in 12-well plates. Transduced cells were selected by puromycin, and
transduction efficiency was confirmed by Western blot, RT-PCR, or both.
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IL-12 p40 and IL-10 concentrations were determined by sandwich ELISA (BD Biosciences,
San Jose, CA).
Western immunoblots
Western blot analyses were performed on whole-cell extracts as described previously (17).
Anti-NFIL3 Ab was obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Statistical analysis
Statistical significance for data subsets was assessed by the two-tailed Student t test unless
specifically described.
Results
NFIL3 is induced in macrophages through a MyD88-dependent pathway
Basal expression of Nfil3 mRNA and protein is detected in murine BMDMs (Fig. 1A, 1B).
Consistent with a prior study (13), LPS induced Nfil3 mRNA (Fig. 1A) and protein (Fig. 1B)
expression in WT BMDMs. LPS and CpG DNA induced Nfil3 expression through an
MyD88-dependent pathway as induction was abrogated in Myd88−/− BMDMs (Fig. 1A,
Supplemental Fig. 1A). Il10−/− mice develop spontaneous chronic enterocolitis dependent
on the presence of the enteric microbiota (20). Interestingly, as reported previously (13),
although basal Nfil3 expression is detected, Nfil3 is not induced in LPS-activated Il10−/−
BMDMs (Fig. 1C). This finding suggested that IL-10 is a cofactor for Nfil3 induction by
LPS. Indeed, LPS-induced Nfil3 expression is abrogated in WT BMDMs in the presence of
anti–IL-10 Abs (Fig. 1D). Moreover, these results indicate that NFIL3 may play a role in the
maintenance of homeostasis to the enteric microbiota. To substantiate this hypothesis, we
characterized colonic Nfil3 expression before and after transition of WT mice from a GF
environment to an SPF microbiota. Colonic Nfil3 expression was significantly induced after
colonization, suggesting that NFIL3 participates in physiological host–enteric microbial
interactions in vivo (Fig. 1E).
Nfil3 is a regulator of Il12b expression
To determine NFIL3 function in macrophages, we compared gene expression profiles in
LPS-activated Nfil3−/− and WT BMDMs by PCR array. Among 84 genes interrogated, Il12b
demonstrated the largest fold increase in Nfil3−/− BMDMs compared with WT BMDMs
(Fig. 2A). Increased Il12b expression was validated by gene-specific real-time RT-PCR (Fig.
2B, left). Moreover, Nfil3−/− BMDMs demonstrated increased IL-12/23 p40 protein
secretion compared with WT BMDMs (Fig. 2B, right). Expression of the IL-12 family
members Il12a and Il23a was similar in LPS-activated Nfil3−/− and WT BMDMs (Fig. 2A,
Supplemental Fig. 1B). However, consistent with increased Il12b expression, increased
IL-12 p70 and IL-23 protein secretion is also observed in Nfil3−/− BMDMs (Supplemental
Fig. 1B). There were no significant differences in cell surface phenotypic or activation
marker expression on Nfil3−/− BMDMs compared with WT BMDMs (Supplemental Fig.
1C).
To exclude possible indirect effects of genetic deletion in Nfil3−/− BMDMs, Nfil3 gene
expression was silenced by lentivirus-mediated short hairpin RNA (shRNA) transduction of
WT BMDMs (Supplemental Fig. 2A). LPS-activated, Nfil3-silenced WT BMDMs
demonstrated significantly higher Il12b expression compared with control scrambled-
shRNA–expressing BMDMs (Fig. 2C).
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To begin to understand how NFIL3 inhibits Il12b, we overexpressed NFIL3 in WT
BMDMs. NFIL3-expressing, lentivirus-transduced WT BMDMs demonstrated significantly
less LPS-induced Il12b (Fig. 2D, left graph; Supplemental Fig. 2B) mRNA and IL-12 p40
protein (Fig. 2D, right graph) compared with control GFP lentivirus-transduced BMDMs.
Two NFIL3 proteins with mutations in a minimal repression domain (9, 21) were
constructed by substituting Lys-330 and Lys-332 to Glu (mutated NFIL3) and deleting the
C-terminal domain from 296 and 462 (truncated NFIL3), respectively (Supplemental Fig.
2C). Expression levels of WT and mutant constructs after lentivirus transduction in BMDMs
were similar (Supplemental Fig. 2D). Both NFIL3 mutant proteins did not fully suppress
LPS-activated Il12b expression compared with intact NFIL3 in WT (Fig. 2E), suggesting
that the inhibitory effect of NFIL3 on Il12b is dependent on the minimal repression domain,
previously shown to be essential for NFIL3 interactions with the TATA-binding protein Dr1
(21). Moreover, NFIL3 expressed in Nfil3−/− BMDMs demonstrated inhibition of LPS-
activated Il12b expression in a concentration-dependent manner, whereas expression of
mutant proteins (mutated NFIL3 and truncated NFIL3) did not affect LPS-induced Il12b
expression (Fig. 2F).
NFIL3 inhibition of Il12b is independent of IL-10
Whether inhibition of Il12b by NFIL3 is mediated through IL-10 was next examined. IL-10
production was similar between WT and Nfil3−/− BMDMs, suggesting that increased
IL-12/23 p40 was not due to impaired IL-10 expression (Fig. 2A, 3A). To confirm this
finding, NFIL3 was overexpressed in Il10−/− BMDMs. Similar to experiments in WT
BMDMs (Fig. 2D), NFIL3 also inhibited LPS-activated Il12b mRNA (Fig. 3B, left graph)
and IL-12 p40 protein (Fig. 3B, right graph) in Il10−/− BMDMs. Likewise, the minimal
repression domain was also required for the inhibition of Il12b by NFIL3 (Fig. 3C). Basal
NFIL3 expression is detected in Il10−/− BMDMs (Fig. 1C). Consequently, knockdown of
NFIL3 by shRNA resulted in increased LPS-induced Il12b in the absence of IL-10 (Fig.
3D). Overall, these results suggest that the inhibitory effect of NFIL3 on Il12b does not
require IL-10.
NFIL3 interacts with the Il12b promoter and inhibits promoter activity
Using a bioinformatics approach (http://www.cbrc.jp/research/db/TFSEARCH.html), we
identified a putative consensus NFIL3 binding site in the Il12b promoter from −269 to −279
upstream of the transcription start site. Furthermore, this binding sequence resides in an
evolutionary conserved region through multiple species including human and mouse
(Supplemental Fig. 3A; http://ecrbrowser.dcode.org), suggesting that it is functionally
important. ChIP experiments from WT BMDMs revealed basal occupancy of NFIL3 on this
binding element (Fig. 4A). NFIL3 occupancy to this promoter region is enhanced in LPS-
activated BMDMs by semiquantitative agarose gel electrophoresis with polyclonal goat IgG
as a negative control (Fig. 4A). Moreover, as expected, no NFIL3 binding to this region is
detected in ChIP experiments from Nfil3−/− BMDMs (Fig. 4B). To demonstrate a direct
effect of NFIL3 on Il12b promoter activity, we used a transformed macrophage line derived
from an Il12b BAC transgenic mouse where a GFP reporter gene was introduced into the
Il12b transcription unit. Lentiviral overexpression of NFIL3 in LPS-activated Il12b-GFP
macrophages resulted in diminished numbers of GFP-expressing cells (Fig. 4C,
Supplemental Fig. 3B). Expression of mutant NFIL3 proteins (mutated NFIL3 and truncated
NFIL3) did not alter the number of LPS-activated GFP+ cells (Fig. 4C). Moreover, in LPS-
activated, Nfil3 shRNA-transduced Il12b-GFP macrophages, increased numbers of GFP+
cells were observed compared with scrambled-shRNA–transduced cells (Fig. 4D,
Supplemental Fig. 3C).
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Induction of NFIL3 by commensal bacteria is impaired in murine and human IBD, which
correlates with increased Il12b expression
To study NFIL3 regulation of Il12b in mucosal innate immunity, we isolated colonic
CD11b+ LPMCs from WT and Nfil3−/− mice, and examined for Il12b expression. CD11b+
LPMCs from Nfil3−/− mice show higher spontaneous Il12b expression than CD11b+ LPMCs
from WT mice (Fig. 5A). Il12b was predominantly expressed in CD11b+ LPMCs in WT and
Nfil3−/− mice, with very low expression in the CD11b− LPMC population. Next, colitis-
prone Il10−/− mice were transitioned from GF to SPF microbiota, and Nfil3 expression was
examined in the colon before and 3 d after transition. Unlike WT mice where colonic Nfil3
expression is significantly induced (Fig. 1E), in Il10−/− mice, colonic Nfil3 is not induced
after transition to SPF microbiota (Fig. 5B).
In humans with IBD, intestinal CD14+ macrophages are important producers of
proinflammatory cytokines including IL-12 family members (5, 22). NFIL3 expression was
significantly lower in CD14+ LPMCs isolated from patients with Crohn’s disease and
ulcerative colitis compared with noninflammatory control subjects (Fig. 5C). It has
previously been demonstrated in the same samples that IL-12 p40 production is increased in
CD14+ LPMCs from IBD patients; thus, NFIL3 expression inversely correlates with greater
levels of IL-12 p40 (5, 6).
Discussion
Macrophages contribute to the functional integrity of the intestinal mucosa in health and
disease through monitoring of luminal contents, prominently the enteric microbiota. Innate
responses are rapid and directed toward conserved structures on infectious agents recognized
by germline-encoded pattern recognition receptors such as TLRs and Nod-like receptors (2).
During physiologic conditions, the default innate immune response to the microbiota is
induction of anti-inflammatory pathways to maintain homeostasis. Defects in this innate
immune “tolerance” to the enteric microbiota are central events in the development of IBD.
However, molecular events mediating physiologic innate homeostasis and chronic intestinal
inflammation are incompletely understood. In this study, NFIL3 is identified as a regulatory
transcription factor in macrophages, controlling macrophage IL-12 p40 production on
interaction with the enteric microbiota. Exposure to commensal bacteria and bacterial
products induced NFIL3 in cultured macrophages and in vivo. Furthermore, colonic CD11b+
LPMCs from Nfil3−/− mice spontaneously expressed Il12b mRNA. This implicates an
important role of microbiota-induced NFIL3 in the maintenance of intestinal homeostasis
through regulation of IL-12 p40.
Il10−/− mice experience development of spontaneous colitis characterized by overexpression
of Il12b in the colon (3). Interestingly, unlike WT mice, Il10−/− mice transitioned from GF
to SPF microbiota demonstrated attenuated induction of colonic Nfil3. We also show that
IL-10 is a cofactor for induction of Nfil3 by bacterial products in BMDMs. Consequently,
the absence of IL-10 in vivo leads to loss of homeostasis and the development of
spontaneous colitis through multiple mechanisms, one of which may be attenuation of Nfil3
induction. In fact, lower expression of NFIL3 was also observed in CD14+ LPMCs from
Crohn’s disease and ulcerative colitis patients. This is consistent with the recent reports
indicating the importance of not directly IL-10, but IL-10–related functional pathways in
both ulcerative colitis and Crohn’s disease, through genetic studies (23, 24). Altered
functional IL-10 pathway may be crucial for the lower expression of NFIL3 in the intestinal
macrophages, resulting in higher IL-12 p40, which is essential for enhanced Th1/Th17
response in patients with IBD. Therefore, how NFIL3 is regulated in macrophages will
provide insight into its function and may guide new therapeutic strategies of IBD. Our
findings indicate that IL-10 is a cofactor for induction of NFIL3 expression in BMDMs and
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in vivo. However, the inhibitory function of NFIL3 on Il12b is independent of IL-10. IL-10
is a well-characterized and biologically significant inhibitor of IL-12 p40 (25). Therefore,
the identification of NFIL3 as an inhibitor of LPS-induced Il12b in macrophages,
independent of the functional effects of IL-10, opens new avenues to understand the
regulation of this central inflammatory gene. NFIL3 induction by microbial stimuli such as
LPS may limit the extent and duration of Il12b expression during physiologic innate
immune responses.
Nonetheless, precise molecular mechanisms of NFIL3-mediated Il12b inhibition remain to
be elucidated. As it interacts with Il12b promoter, NFIL3 may recruit a corepressor. One
candidate is the TATA-binding protein Dr1. We show that the inhibitory effect of NFIL3 on
Il12b is dependent on amino acids 330 and 332, essential for interactions with Dr1 (21).
Moreover, interactions between NFIL3 and other transcription factors may ultimately
determine the complexities of Il12b regulation. Many reported proteins recognize similar
DNA sequences, such as CREB, ATF3, and HLF (9). Indeed, ATF3 previously has been
demonstrated to be a regulator of Il12b transcription (26). Based on the described
transcriptional regulatory functions of NFIL3, we speculate that NFIL3 regulates Il12b
through chromatin modifications. This hypothesis will need to be tested in future studies
through detailed mapping and mutagenesis of NFIL3 sites within the endogenous Il12b
locus, because of limitations of transient transfection of minimal promoter constructs to
address these questions.
In humans, intestinal macrophages express low levels of cell surface innate immune
receptors such as TLR4 and CD14, which contributes to their anti-inflammatory functional
phenotype. However, in IBD patients, CD14-expressing macrophages are increased in
number, and these cells produce proinflammatory cytokines including IL-12/23, in response
to enteric bacteria (5). CD14+ LPMCs have been demonstrated to directly activate the Th1/
Th17 immune response in Crohn’s disease (27). Our results in human intestinal CD14+
LPMCs suggest that NFIL3 may be important for intestinal macrophages to acquire a
hyporesponsive phenotype, and impaired NFIL3 expression may shift tolerogenic functions
to proinflammatory.
Through a gene expression array, NFIL3 was identified as a fairly specific regulator of
Il12b. However, Il6 was another proinflammatory cytokine gene upregulated in LPS-
activated Nfil3−/− BMDMs (Fig. 2A). The Il6 promoter also contains putative binding sites
for NFIL3. IL-6 is essential for the development of Th17 cells (28, 29). Therefore, NFIL3
may serve as a molecular link between innate and adaptive immunity, shaping Th1 and Th17
responses in vivo.
NFIL3 joins a growing list of factors important for the maintenance of intestinal
homeostasis. It is plausible that NFIL3 has a much broader role in anti-inflammatory innate
immune responses than described in this study, perhaps through gene regulation in concert
with other proteins that share the same binding sequences. In conclusion, these experiments
implicate NFIL3 as a microbiota-induced Il12b transcriptional inhibitor, involved in the
maintenance of intestinal homeostasis.
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Nfil3 is induced by bacterial products in cultured BMDMs and the enteric microbiota in
vivo. A, WT and Myd88−/− BMDMs were stimulated with LPS (10 ng/ml) for 0.5, 1, 2, and
3 h, and Nfil3 expression was analyzed by real-time RT-PCR. Results are expressed as fold
induction versus unstimulated WT BMDMs normalized to β-actin (representative from three
independent experiments). B, WT BMDMs were analyzed for NFIL3 protein by Western
immunoblot. WT BMDMs were stimulated with LPS (100 ng/ml) for 3, 6, and 16 h. Results
are representative from four independent experiments. C, WT and Il10−/− BMDMs were
stimulated with LPS for 1, 2, and 3 h, and kinetics of Nfil3 expression was analyzed by real-
time RT-PCR. Results are expressed as fold induction versus unstimulated WT BMDMs
normalized to β-actin (mean ± SEM from four independent experiments). D, WT BMDMs
were stimulated with LPS in the presence of anti–IL-10 Ab (10 μg/ml) or isotype control Ab
(10 μg/ml) for 2, 4, and 8 h, and kinetics of Nfil3 expression was analyzed by real-time RT-
PCR. Results are expressed as fold induction versus unstimulated WT BMDMs normalized
to β-actin (mean ± SEM from four independent experiments). E, GF WT mice were
transitioned to an SPF enteric microbiota and colonic Nfil3 expression was analyzed before
and 3 and 14 d postcolonization. Results are expressed as fold induction versus GF colons
normalized to β-actin (mean ± SEM from three independent experiments). *p < 0.05, **p <
0.01 versus GF.
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Nfil3−/− macrophages demonstrate increased Il12b expression. A, WT and Nfil3−/− BMDMs
were stimulated with LPS (10 ng/ml) for 4 h, and mRNA expression was quantified by PCR
array (SA Biosciences). Relative mRNA expression for Il12a, Il12b, Il23a, Tnf, Il6, and Il10
in Nfil3−/− BMDMs compared with WT BMDMs are shown. Results are representative
from two independent experiments. B, WT and Nfil3−/− BMDMs were stimulated with LPS
(10 ng/ml), and Il12b mRNA (4 h post-LPS) and IL-12 p40 protein (24 h post-LPS) were
analyzed by real-time RT-PCR and ELISA. Il12b results are expressed as fold induction
versus unstimulated WT BMDMs. All results represent mean ± SEM of four independent
experiments. *p < 0.05 versus LPS-stimulated WT BMDMs. C, WT BMDMs transduced
with lentiviral expressed Nfil3 shRNA and control scrambled shRNA were stimulated with
LPS for 3 h for Il12b expression analysis. Results are expressed as fold induction versus
unstimulated BMDMs transduced with scrambled shRNA (mean ± SEM from four
independent experiments). *p < 0.05 versus scrambled shRNA transduced BMDMs
stimulated with LPS. D, WT BMDMs transduced with lentivirus to express NFIL3 or GFP
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(control) were stimulated with LPS (10 ng/ml). Il12b mRNA (3 h post-LPS) and IL-12 p40
protein (24 h post-LPS) were determined. Results for mRNA are expressed as fold induction
versus unstimulated GFP transduced BMDMs normalized to β-actin (mean ± SEM from
three independent experiments). *p < 0.05 versus LPS-stimulated GFP-transduced BMDMs.
E, WT BMDMs transduced with lentivirus that expressed WT, mutated, and truncated
NFIL3 were stimulated with LPS for 4 h. See text for description of protein constructs.
Results are expressed as percent induction versus LPS-stimulated GFP-transduced BMDMs
normalized to β-actin (mean ± SEM from three independent experiments). *p < 0.01 versus
LPS-stimulated GFP-expressing BMDMs were calculated. F, WT and Nfil3−/− BMDMs
transduced with different titers of lentivirus-expressed NFIL3 constructs were stimulated
with LPS for 4 h and analyzed for Il12b and Nfil3 expression. Il12b expressions are
presented as percent induction versus LPS-stimulated GFP-transduced WT BMDMs
normalized to β-actin. Nfil3 expression is presented as relative induction versus unstimulated
GFP-transduced WT BMDMs normalized to β-actin.
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NFIL3 inhibition of Il12b is independent of IL-10. A, WT and Nfil3−/− BMDMs were
stimulated with LPS (10 ng/ml), and Il10 mRNA (4 h post-LPS) and IL-10 protein (24 h
post-LPS) were analyzed by real-time RT-PCR and ELISA. Il10 results are expressed as
fold induction versus unstimulated WT BMDMs. Results represent mean ± SEM of four
independent experiments. B, Il10−/− BMDMs transduced with lentivirus to express NFIL3
or GFP were stimulated with LPS (10 ng/ml). Il12b mRNA (3 h post-LPS, left panel) and
IL-12 p40 protein (24 h post-LPS, right panel) were determined. Results for mRNA are
expressed as fold induction versus unstimulated GFP-transduced BMDMs normalized to β-
actin (mean ± SEM from three independent experiments). **p < 0.01 versus LPS-stimulated
GFP-transduced BMDMs. C, Il10−/− BMDMs transduced with lentivirus that expressed
WT, mutated (Mut), and truncated (Trunc) NFIL3 were stimulated with LPS for 4 h. Results
are expressed as percent induction versus LPS-stimulated GFP-transduced BMDMs
normalized to β-actin (mean ± SEM from three independent experiments). *p < 0.01 versus
LPS-stimulated GFP-expressing BMDMs. D, Il10−/− BMDMs transduced with lentiviral
that expressed Nfil3 shRNA and control scrambled shRNA were stimulated with LPS for 3 h
for Il12b expression analysis. Results are expressed as fold induction versus unstimulated
BMDMs transduced with scrambled shRNA (mean ± SEM from four independent
experiments). *p < 0.05 versus scrambled shRNA-transduced BMDMs stimulated with LPS
by paired t test.
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NFIL3 inhibits Il12b through interactions with the promoter. A, Recruitment of NFIL3 on
the Il12b promoter was analyzed by ChIP. Induction of NFIL3-binding activity to the Il12b
promoter was confirmed by ChIP with PCR products visualized on a 2% agarose gel. WT
BMDMs were stimulated with or without LPS (100 ng/ml) for 3 h. Polyclonal goat IgG
(first lane) is a negative control. This result is representative of three independent chromatin
preparations. B, In separate experiments, WT and Nfil3−/− BMDMs were stimulated with or
without LPS (100 ng/ml) for 3 h. Quantitative results are presented as enrichment
(percentage input DNA) of NFIL3 binding to the Il12b promoter and are representative of
three independent chromatin preparations. C, Il12b-GFP transformed macrophages
transduced with empty (control), WT, 2-aa mutated (Mut) or truncated (Trunc) NFIL3 were
stimulated with 100 ng/ml LPS for 24 h and analyzed by FACS. Representative histograms
with mean fluorescent intensity are given. Percentage of GFP+ cells relative to control is
also shown (mean ± SEM from three independent experiments). *p < 0.05 versus control. D,
Il12b-GFP macrophages were transduced with scrambled or NFIL3-shRNA. Cells were
stimulated with 10 ng/ml LPS for 24 h and analyzed by FACS. Representative histograms
with mean fluorescent intensity are given. Data are presented as percentage of GFP+ cells
relative to scrambled shRNA-treated cells (mean ± SEM from three independent
experiments). *p < 0.05 versus scrambled shRNA.
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Induction of NFIL3 by commensal bacteria is impaired in murine and human IBD. A,
Colonic CD11b+ and CD11b− LPMCs from WT and Nfil3−/− mice were analyzed for Il12b
expression. Results are presented as expression relative to WT 11b+ LPMCs normalized to
β-actin (mean ± SEM from three independent experiments). B, GF WT and colitis-prone
Il10−/− mice were transitioned to an SPF enteric microbiota, and colonic Nfil3 expression
was analyzed 3 d postcolonization. Results are expressed as fold induction versus WT GF
colons normalized to β-actin (mean ± SEM from three independent experiments). *p < 0.05
versus GF. C, NFIL3 expression in human CD14+ LPMCs was examined (control [cont], n
= 8; Crohn’s disease [CD], n = 8; ulcerative colitis [UC], n = 8). Results are presented as
relative expression compared with controls normalized to β-actin (mean ± SEM). *p < 0.05,
**p < 0.01 versus control (Dunnett’s multiple-comparison test).
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